Salarius Pharmaceuticals Operating Expenses 2011-2026 | SLRX

Annual Operating Expenses Salarius Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
12.6 M	5.73 M	12.9 M	31.8 M	14.7 M	13 M	11.7 M	22.5 M	35.5 M	40.2 M	29.2 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
40.2 M	5.73 M	20.9 M

Quarterly Operating Expenses Salarius Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
895 K	966 K	1.72 M	-	1.01 M	1.47 M	1.77 M	-	2.53 M	3.97 M	5.42 M	-	14.5 M	4.76 M	6.12 M	-	3.75 M	3.69 M	3.07 M	-	3.14 M	3.14 M	3.5 M	-	4.64 M	1.81 M	2.19 M	2.18 M	783 K	9.35 M	8.46 M	8.38 M	9.82 M	9.21 M	8.59 M	8.28 M	11.3 M	11.6 M	9.7 M	7.93 M	8.17 M	7.09 M	6.02 M	3.75 M	1.99 M	2.19 M	92.7 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14.5 M	92.7 K	5.1 M

Operating Expenses of other stocks in the Biotechnology industry

Issuer	Operating Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	432 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	206 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	140 M	-	-	$ 86.2 M	USA
ACADIA Pharmaceuticals ACAD	708 M	$ 22.56	2.13 %	$ 3.74 B	USA
AlloVir ALVR	46.2 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	127 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	74.5 M	-	-	$ 8.42 M	USA
Akebia Therapeutics AKBA	173 M	$ 1.43	3.62 %	$ 368 M	USA
argenx SE ARGX	3.19 B	$ 785.07	2.57 %	$ 25 B	Niderland
I-Mab IMAB	1.49 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.66 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	78.3 M	-	2.54 %	$ 160 B	France
Alnylam Pharmaceuticals ALNY	1.13 B	$ 327.25	2.42 %	$ 42.9 B	USA
Aytu BioScience AYTU	53.7 M	$ 2.66	3.5 %	$ 16.7 M	USA
AVROBIO AVRO	71.7 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	29.8 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	17.6 B	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	4.78 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	8.22 M	-	-1.52 %	$ 24.7 M	USA
BeiGene, Ltd. BGNE	390 M	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	16.7 M	$ 3.9	3.7 %	$ 9.38 B	Australia
CymaBay Therapeutics CBAY	133 M	-	-	$ 3.45 B	USA
Advaxis ADXS	22 M	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	216 M	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	85.5 M	$ 4.18	1.21 %	$ 447 M	USA
Avid Bioservices CDMO	26 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	177 M	-	-	$ 1.41 B	USA
Институт стволовых клеток человека ISKJ	629 M	-	-	-	Russia
Arcutis Biotherapeutics ARQT	137 M	$ 24.61	5.76 %	$ 3.13 B	USA
Cabaletta Bio CABA	172 M	$ 3.09	0.65 %	$ 310 M	USA
Checkpoint Therapeutics CKPT	56.2 M	-	-	$ 169 M	USA
Aeterna Zentaris AEZS	23 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	61.5 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	24.2 M	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	110 M	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	210 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.5 M	-	-	$ 26.5 M	USA
Autolus Therapeutics plc AUTL	145 M	$ 1.49	9.56 %	$ 397 M	Britain
CTI BioPharma Corp. CTIC	47.8 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	179 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	24.7 M	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	9.17 M	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	226 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	80.2 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	137 M	-	-	$ 2.02 B	USA
Forte Biosciences FBRX	70.7 M	$ 26.27	0.38 %	$ 340 M	USA
CureVac N.V. CVAC	88.9 M	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	17.3 M	$ 3.88	2.11 %	$ 261 B	Britain
Akouos AKUS	86.8 M	-	0.23 %	$ 488 M	USA